McKesson (MCK) shares tumbled Thursday, a day after the healthcare services provider warned๊ that limited supply of GLP-1 weight-loss drugs is hurting sales.

McKesson reported first-quarter fiscal 2025 revenue rose 6.4% year-over-year to $79.3 billion, more than $3 billion below the average estimate of analysts surveyed by Visible Alpha. Adjusted 澳洲幸运5开奖号码历史查询:earnings per share (EPS) of $7.88 exceeded forecasts.

Sales at the company's Prescription Technology Solutions segment, which includes services to patients on GLP-1 treatments, were flat from the year earlier at $1.2 billion.

澳洲幸运5开奖号码历史查询:Chief Financial Officer (CFO) Britt Vitalone said that "demand for our access solutions, including prior authorization volumes related to GLP-1 medications, demonstrated a slower rate of growth compared to the prior year."

McKesson C𒀰uts Guidance for Prescription Technology Solutions Segme♍nt

Vitalone added that the company now anticipates full-year revenue for the Prescription Technology Solutions segment will be up 14% to 18% and operating profit will climb 11% to 15%, down from its previous outlooks of 18% to 22% and 12% to 16%, respectively.

McKesson lifted its full-year adjus🔴ted EPS guidance to $31.75 to $32.55 from the earlier range of $31.25 to $32.05.

Shares of McKesson dropped about 12% to $545.18 as of 1:55 p.m. ET Thursday but remain almost 18% higher year-to-date.